Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing de...
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, announced that it h...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company develo...
Helvoet is an advanced medical CDMO specializing in highly automated micro-molding and precision injection molding for microfluidics, diagnostics, an...
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), me...
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery...
Bavarian Nordic A/S announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikung...
First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 cli...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug rep...
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of He...
Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities AstraZen...
Complaint filed in San Diego County Superior Court seeks specific performance, alleging NRx warranted it had funds to close while concealing it lacked ...
© 2026 Biopharma Boardroom. All Rights Reserved.
